Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

G Oskay-Özcelik, S Alavi, R Richter, M Keller, R Chekerov, S C Cecere, G Cormio, F Joly, J E Kurtz, A du Bois, M Maciejewski, M Jedryka, I Vergote, E Van Nieuwenhuysen, A Casado, C Mendiola, P Achimas-Cadariu, C Vlad, D Reimer, A G ZeimetM Friedlander, J Sehouli

Research output: Contribution to journalArticle

Abstract

Backround: The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment.

Patients and methods: A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version.

Results: From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included.

Conclusion: This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.

Original languageEnglish
Pages (from-to)910-916
Number of pages7
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Physician-Patient Relations
Patient Preference
Ovarian Neoplasms
Therapeutics
Alopecia
Fatigue
Romania
Austria
Belgium
Poland
Internet
Spain
Italy
France
Germany
Clinical Trials

Cite this

Expression III : patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. / Oskay-Özcelik, G; Alavi, S; Richter, R; Keller, M; Chekerov, R; Cecere, S C; Cormio, G; Joly, F; Kurtz, J E; du Bois, A; Maciejewski, M; Jedryka, M; Vergote, I; Van Nieuwenhuysen, E; Casado, A; Mendiola, C; Achimas-Cadariu, P; Vlad, C; Reimer, D; Zeimet, A G; Friedlander, M; Sehouli, J.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, No. 4, 01.04.2018, p. 910-916.

Research output: Contribution to journalArticle

Oskay-Özcelik, G, Alavi, S, Richter, R, Keller, M, Chekerov, R, Cecere, SC, Cormio, G, Joly, F, Kurtz, JE, du Bois, A, Maciejewski, M, Jedryka, M, Vergote, I, Van Nieuwenhuysen, E, Casado, A, Mendiola, C, Achimas-Cadariu, P, Vlad, C, Reimer, D, Zeimet, AG, Friedlander, M & Sehouli, J 2018, 'Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, no. 4, pp. 910-916. https://doi.org/10.1093/annonc/mdy037
Oskay-Özcelik, G ; Alavi, S ; Richter, R ; Keller, M ; Chekerov, R ; Cecere, S C ; Cormio, G ; Joly, F ; Kurtz, J E ; du Bois, A ; Maciejewski, M ; Jedryka, M ; Vergote, I ; Van Nieuwenhuysen, E ; Casado, A ; Mendiola, C ; Achimas-Cadariu, P ; Vlad, C ; Reimer, D ; Zeimet, A G ; Friedlander, M ; Sehouli, J. / Expression III : patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29, No. 4. pp. 910-916.
@article{350d442fda4640149e5237d06f583790,
title = "Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries",
abstract = "Backround: The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment.Patients and methods: A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version.Results: From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3{\%}) after initial diagnosis and 731 (39.9{\%}) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2{\%}) had experienced upfront surgery followed by first-line chemotherapy (91.8{\%}). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42{\%}), 'there must be more done to counter fatigue' (34.5{\%}) and 'the therapy should be more effective' (29.7{\%}). Out of 659 (36{\%}) patients, who were offered participation in a clinical trial, 476 (26{\%}) were included.Conclusion: This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.",
author = "G Oskay-{\"O}zcelik and S Alavi and R Richter and M Keller and R Chekerov and Cecere, {S C} and G Cormio and F Joly and Kurtz, {J E} and {du Bois}, A and M Maciejewski and M Jedryka and I Vergote and {Van Nieuwenhuysen}, E and A Casado and C Mendiola and P Achimas-Cadariu and C Vlad and D Reimer and Zeimet, {A G} and M Friedlander and J Sehouli",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/annonc/mdy037",
language = "English",
volume = "29",
pages = "910--916",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Expression III

T2 - patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

AU - Oskay-Özcelik, G

AU - Alavi, S

AU - Richter, R

AU - Keller, M

AU - Chekerov, R

AU - Cecere, S C

AU - Cormio, G

AU - Joly, F

AU - Kurtz, J E

AU - du Bois, A

AU - Maciejewski, M

AU - Jedryka, M

AU - Vergote, I

AU - Van Nieuwenhuysen, E

AU - Casado, A

AU - Mendiola, C

AU - Achimas-Cadariu, P

AU - Vlad, C

AU - Reimer, D

AU - Zeimet, A G

AU - Friedlander, M

AU - Sehouli, J

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Backround: The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment.Patients and methods: A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version.Results: From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included.Conclusion: This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.

AB - Backround: The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment.Patients and methods: A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version.Results: From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included.Conclusion: This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.

U2 - 10.1093/annonc/mdy037

DO - 10.1093/annonc/mdy037

M3 - Article

C2 - 29415128

VL - 29

SP - 910

EP - 916

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -